November 2024

INDIANAPOLIS, Nov. 1, 2024 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that data from the Phase 3 trial (EMBER-3) for imlunestrant, an oral selective estrogen receptor degrader (SERD), will be reported for the first time in a late-breaking oral presentation at the San Ant

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: